Briakinumab vs placebo
Failure to induce clinical remission at end of study · induction of remission in Crohn's disease
Briakinumab showed no clear difference in failure to induce clinical remission (Mannon 2004) CDAI (≤150 points) compared with placebo (low certainty).
1 finding from 1 review
- Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 0.86 [0.65, 1.14]1 study · 79 participantsLow